Table 3.
Treatment-related TEAE that occurred in >10% of patients.
| Patients (N = 31) | ||
|---|---|---|
| MedDRA preferred term, n (%) | Any grade | Grade 3/4 |
| Patients with any treatment-related TEAE | 30 (96.8) | 25 (80.6) |
| Neutropenia | 24 (77.4) | 22 (71.0) |
| Leukopenia | 23 (74.2) | 16 (51.6) |
| Decreased appetite | 16 (51.6) | 2 (6.5) |
| Anemia | 14 (45.2) | 6 (19.4) |
| Pyrexia | 13 (41.9) | 0 |
| Thrombocytopenia | 12 (38.7) | 4 (12.9) |
| Stomatitis | 12 (38.7) | 0 |
| Nausea | 9 (29.0) | 0 |
| Febrile neutropenia | 7 (22.6) | 7 (22.6) |
| Infusion-related reaction | 7 (22.6) | 0 |
| Dysgeusia | 6 (19.4) | 0 |
| Malaise | 5 (16.1) | 0 |
| Fatigue | 5 (16.1) | 0 |
| Vomiting | 4 (12.9) | 0 |
| Hypothyroidism | 4 (12.9) | 0 |
Abbreviation: MedDRA, Medical Dictionary for Regulatory Activities.